Teva North America has over 6,000 employees in various sites throughout the US, Canada and Puerto Rico. One in every six prescriptions dispensed in the U.S. and one in every seven dispensed in Canada is a Teva product. The Latin America Unit markets a broad portfolio of products distributed to many countries across the region. The largest markets in the region are Brazil, Mexico, Venezuela, Colombia and Argentina. Products are primarily manufactured at the Teva Group production facilities in Mexico, Chile, Argentina and Peru.
Teva Asia is responsible of commercial & sales activities in Japan, China, India and other countries across Asia
EMIA is a newly formed division within Teva, coordinating all commercial activities in Eastern Europe, Israel, the Middle East and Africa. Headquartered in Israel, EMIA's representatives are positioned across the region, overseeing all activities, including marketing, registration, logistics and distribution. EMIA's people are committed to maintain fruitful, ongoing relationships with local communities and to achieve sustained profitable growth in each market.
Teva Pharmaceuticals Europe B.V. is the European commercial arm of Teva Pharmaceutical Industries, handling the second-largest market within Teva, with $3.94 billion sales in 2010. With 13,000 employees in 27 European Union member states, as well as in Norway and Switzerland, Teva, following the ratiopharm acquisition, is now the leading generics company in Europe. Headquartered in the Netherlands, Teva Europe specializes in the development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and Active Pharmaceutical Ingredients (APIs).